Digestive Health Center

  • Inflammatory and Diarrheal Diseases

    Bruce R. Yacyshyn, MD, FRCPC, ABIM, FACG
    Professor
    Department of Internal Medicine; Division of Digestive Diseases

    Description of Research

    The goal of Dr. Yacyshyn’s research is to investigate biomarkers for inflammatory bowel disease (IBD) using proteomics and genomics. In addition, his laboratory has maintained a focus in the identification and establishment of new approaches to the prevention and early treatment of intestinal inflammation. Dr. Yacyshyn specifically plans to study the relationship between dietary fiber supplementation and the maintenance of remission in patients in ulcerative colitis. He and colleagues have developed new drugs and diagnostic tests for the treatment of IBD. During a recent retooling and further honing of IBD skills in industry, Dr. Yacyshyn was responsible for the development of new drugs by designing clinical trials, initiating difficult-to-recruit trials in the maintenance and treatment of IBD, identifying new biomarkers, and obtaining new drug approval letters from the Food and Drug Administration (FDA) after successful completion of these projects.

    Collaborations

    Dr. Yacyshyn collaborates with Drs. Denson and Hogan investigating biomarkers in inflammatory bowel disease, and assessing the effects of new treatment regimens on gut permeability in animal models of intestinal inflammation. Anticipated use of Cores: Integrative Morphology Core.

 
  • Research image.

    click to enlarge

    Research image.

    Treatment success at week 6 in patients having taken previous ulcerative colitis (UC) therapy. An advantage of 4.8 g/day versus 2.4 g/day was observed with patients previously treated with oral mesalamines (P = .07), rectal therapies (P = .06), corticosteroids (P = .05), or multiple UC medications (P = .01). Figure from Gastroenterology, 2009;137:1934-43.e1-3.